ITGB1 and neoplasm: In this group, patients with ITGB1 expression in the tumor showed a median OS of 10.2 months (95% CI 1.9–41.7 months) compared to a median OS of 31.4 months (95% CI 21.1–144.2 months, P = 0.008) in the group without ITGB1 expression (Fig. 2).